Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2008 1
2009 2
2010 2
2011 3
2012 4
2013 1
2014 2
2015 2
2016 4
2017 6
2018 9
2019 7
2020 9
2021 16
2022 28
2023 16
2024 20
2025 15

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

126 results

Results by year

Filters applied: . Clear all
Page 1
Allergic and eosinophilic asthma in the era of biomarkers and biologics: similarities, differences and misconceptions.
Oppenheimer J, Hoyte FCL, Phipatanakul W, Silver J, Howarth P, Lugogo NL. Oppenheimer J, et al. Among authors: lugogo nl. Ann Allergy Asthma Immunol. 2022 Aug;129(2):169-180. doi: 10.1016/j.anai.2022.02.021. Epub 2022 Mar 7. Ann Allergy Asthma Immunol. 2022. PMID: 35272048 Free article. Review.
We sought to better understand the similarities and differences between allergic and eosinophilic asthma and highlight where misconceptions may arise. DATA SOURCES: Published articles, pivotal trials, post hoc analyses, and asthma clinical guidelines sourced from Pu …
We sought to better understand the similarities and differences between allergic and eosinophilic asthma and highlight where misconce …
Asthma.
Smith JD, Arteta M, Baptist AP, Van Harrison R, Kelley SA, Lindell VA, Lugogo NL, Noble JA, Rew KT, Van Harrison R, Proudlock AL. Smith JD, et al. Among authors: lugogo nl. Ann Arbor (MI): Michigan Medicine University of Michigan; 2021 Jul. Ann Arbor (MI): Michigan Medicine University of Michigan; 2021 Jul. PMID: 35412724 Free Books & Documents. Review.
This guideline provides evidence-based guidance to improve quality of life for patients with asthma. Control asthma symptoms at rest and during exercise. Attain normal lung function. Minimize adverse drug reactions. Prevent asthma exacerbations. Attain normal …
This guideline provides evidence-based guidance to improve quality of life for patients with asthma. Control asthma symptoms a …
Consensus of an American College of Allergy, Asthma, and Immunology, American Academy of Allergy, Asthma, and Immunology, and American Thoracic Society workgroup on definition of clinical remission in asthma on treatment.
Blaiss M, Oppenheimer J, Corbett M, Bacharier L, Bernstein J, Carr T, Chipps B, Couillard S, Forno E, Grant T, Lugogo N, May K, Schauberger E. Blaiss M, et al. Among authors: lugogo n. Ann Allergy Asthma Immunol. 2023 Dec;131(6):782-785. doi: 10.1016/j.anai.2023.08.609. Epub 2023 Sep 8. Ann Allergy Asthma Immunol. 2023. PMID: 37690606 No abstract available.
Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma.
Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, Barker P, Sproule S, Ponnarambil S, Goldman M; ZONDA Trial Investigators. Nair P, et al. Among authors: lugogo nl. N Engl J Med. 2017 Jun 22;376(25):2448-2458. doi: 10.1056/NEJMoa1703501. Epub 2017 May 22. N Engl J Med. 2017. PMID: 28530840 Free article. Clinical Trial.
BACKGROUND: Many patients with severe asthma rely on oral glucocorticoids to manage their disease. We investigated whether benralizumab, a monoclonal antibody directed against the alpha subunit of the interleukin-5 receptor that significantly reduces the incidence of as …
BACKGROUND: Many patients with severe asthma rely on oral glucocorticoids to manage their disease. We investigated whether benralizum …
Tezepelumab for Severe Asthma: One Drug Targeting Multiple Disease Pathways and Patient Types.
Panettieri R Jr, Lugogo N, Corren J, Ambrose CS. Panettieri R Jr, et al. Among authors: lugogo n. J Asthma Allergy. 2024 Mar 19;17:219-236. doi: 10.2147/JAA.S342391. eCollection 2024. J Asthma Allergy. 2024. PMID: 38524099 Free PMC article. Review.
Here we describe the anti-inflammatory effects and efficacy of tezepelumab across the most relevant phenotypes of severe asthma. Across clinical studies, tezepelumab reduced annualized asthma exacerbation rates versus placebo by 63-71% in eosinophilic severe asth …
Here we describe the anti-inflammatory effects and efficacy of tezepelumab across the most relevant phenotypes of severe asthma. Acro …
Reply.
Lugogo NL, Green C, Kraft M. Lugogo NL, et al. J Allergy Clin Immunol. 2018 Aug;142(2):713-714. doi: 10.1016/j.jaci.2018.02.030. Epub 2018 Apr 11. J Allergy Clin Immunol. 2018. PMID: 29655585 No abstract available.
Cluster Analysis of Inflammatory Biomarker Expression in the International Severe Asthma Registry.
Denton E, Price DB, Tran TN, Canonica GW, Menzies-Gow A, FitzGerald JM, Sadatsafavi M, Perez de Llano L, Christoff G, Quinton A, Rhee CK, Brusselle G, Ulrik C, Lugogo N, Hore-Lacy F, Chaudhry I, Bulathsinhala L, Murray RB, Carter VA, Hew M. Denton E, et al. Among authors: lugogo n. J Allergy Clin Immunol Pract. 2021 Jul;9(7):2680-2688.e7. doi: 10.1016/j.jaip.2021.02.059. Epub 2021 Mar 18. J Allergy Clin Immunol Pract. 2021. PMID: 33744476 Free article.
BACKGROUND: Allergy, eosinophilic inflammation, and epithelial dysregulation are implicated in severe asthma pathogenesis. OBJECTIVE: We characterized biomarker expression in adults with severe asthma. METHODS: Within the International Severe Asthma Registry …
BACKGROUND: Allergy, eosinophilic inflammation, and epithelial dysregulation are implicated in severe asthma pathogenesis. OBJECTIVE: …
Biologics in Asthma: Emerging Biologics.
Desai B, Adrish M, Mohan A, Lugogo NL. Desai B, et al. Among authors: lugogo nl. Immunol Allergy Clin North Am. 2024 Nov;44(4):751-763. doi: 10.1016/j.iac.2024.07.008. Epub 2024 Aug 22. Immunol Allergy Clin North Am. 2024. PMID: 39389722 Review.
Advances in our understanding of asthma pathophysiology have led to the advent of multiple targeted asthma therapies such as biologics. ...Therefore, although our current focus is on biologics; it is critical to take a more holistic approach including consideration …
Advances in our understanding of asthma pathophysiology have led to the advent of multiple targeted asthma therapies such as b …
Mometasone or Tiotropium in Mild Asthma with a Low Sputum Eosinophil Level.
Lazarus SC, Krishnan JA, King TS, Lang JE, Blake KV, Covar R, Lugogo N, Wenzel S, Chinchilli VM, Mauger DT, Dyer AM, Boushey HA, Fahy JV, Woodruff PG, Bacharier LB, Cabana MD, Cardet JC, Castro M, Chmiel J, Denlinger L, DiMango E, Fitzpatrick AM, Gentile D, Hastie A, Holguin F, Israel E, Jackson D, Kraft M, LaForce C, Lemanske RF Jr, Martinez FD, Moore W, Morgan WJ, Moy JN, Myers R, Peters SP, Phipatanakul W, Pongracic JA, Que L, Ross K, Smith L, Szefler SJ, Wechsler ME, Sorkness CA; National Heart, Lung, and Blood Institute AsthmaNet. Lazarus SC, et al. Among authors: lugogo n. N Engl J Med. 2019 May 23;380(21):2009-2019. doi: 10.1056/NEJMoa1814917. Epub 2019 May 19. N Engl J Med. 2019. PMID: 31112384 Free PMC article. Clinical Trial.
BACKGROUND: In many patients with mild, persistent asthma, the percentage of eosinophils in sputum is less than 2% (low eosinophil level). ...CONCLUSIONS: The majority of patients with mild, persistent asthma had a low sputum eosinophil level and had no significant …
BACKGROUND: In many patients with mild, persistent asthma, the percentage of eosinophils in sputum is less than 2% (low eosinophil le …
Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies.
Wechsler ME, Brusselle G, Virchow JC, Bourdin A, Kostikas K, Llanos JP, Roseti SL, Ambrose CS, Hunter G, Jackson DJ, Castro M, Lugogo N, Pavord ID, Martin N, Brightling CE. Wechsler ME, et al. Among authors: lugogo n. Eur Respir J. 2024 Dec 5;64(6):2400316. doi: 10.1183/13993003.00316-2024. Print 2024 Dec. Eur Respir J. 2024. PMID: 39326921 Free PMC article. Clinical Trial.
BACKGROUND: In asthma, clinical response is characterised by disease improvement with treatment, whereas clinical remission is characterised by long-term disease stabilisation with or without ongoing treatment. ...Complete clinical response was defined as achieving all of …
BACKGROUND: In asthma, clinical response is characterised by disease improvement with treatment, whereas clinical remission is charac …
126 results